CXCL8 and irritable bowel syndrome: A decreased amount of F. prausnitzii has been noted in patients with IBD, which is also known to secrete metabolites that impede nuclear factor-κappaB activation and IL-8 production, ultimately leading to anti-inflammatory effects (18,19).